Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
ConclusionThe results from the VERTIS-CV trial will define the CV and renal safety and efficacy of ertugliflozin in patients with T2DM and ASCVD.ClinicalTrials.gov identifier: NCT01986881
Source: American Heart Journal - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Dialysis | Endocrinology | Heart | Heart Attack | Heart Failure | Heart Transplant | Kidney Transplant | Kidney Transplantation | SGLT2 Inhibitors | Sodium | Stroke | Transplant Surgery | Transplants | Urology & Nephrology | USA Health